上海
分享至
贝达药业1月4日公告，公司申报的BPI-460372片药品临床试验已获得国家药品监督管理局批准开展晚期实体瘤的临床试验。
特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
